New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Prelude Therapeutics Incorporated (PRLD) vs Turn Therapeutics Inc. (TTRX)

Prelude Therapeutics Incorporated and Turn Therapeutics Inc. are both Biotechnology companies. Prelude Therapeutics Incorporated and Turn Therapeutics Inc. are of similar size ($264.2M and $260.5M). Across the 10 metrics below, Prelude Therapeutics Incorporated leads on 7 and Turn Therapeutics Inc. on 3.

Valuation

Metric PRLD TTRX Biotechnology median
P/E n/m n/m 8.49
P/S 15.44 — 8.56
P/B 2.68 42.46 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 8.95 — 8.00
Earnings yield (18.32%) (5.32%) (35.81%)
Free cash flow yield (8.40%) (2.21%) (25.41%)

Profitability

Metric PRLD TTRX Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (283.92%) — 0.00%
Net margin (247.12%) — 0.00%
Free cash flow margin (129.68%) — 0.00%
Return on equity (58.36%) (412.27%) (51.58%)
Return on assets (39.45%) (123.72%) (45.91%)
Return on invested capital 0.00% (291.26%) 0.00%

Growth

Metric PRLD TTRX Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 23.21% (80.72%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric PRLD TTRX Biotechnology median
Debt to equity 0.00 1.09 0.00
Current ratio 4.20 3.19 4.79
Net debt to EBITDA 1.00 0.96 1.01

Dividend

Metric PRLD TTRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PRLD TTRX Biotechnology median
Market cap 260.48m 264.15m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack